Investor Relations

A leadership story in the field of advanced cell therapy

Investor Relations

Press Releases

Aastrom Biosciences CEO to Present at Rodman & Renshaw Techvest 7th Annual Healthcare Conference

November 3, 2005 at 12:00 AM EST
Aastrom Biosciences CEO to Present at Rodman & Renshaw Techvest 7th Annual Healthcare Conference

Ann Arbor, Michigan, November 3, 2005 -- Aastrom Biosciences, Inc. (Nasdaq: ASTM) announced today R. Douglas Armstrong, Ph.D., Chairman and Chief Executive Officer, will present at the Rodman & Renshaw Techvest 7th Annual Healthcare Conference. The conference will be held November 7-9, 2005 at the New York Palace Hotel in New York, NY. Dr. Armstrong will present at 10:10 a.m. (ET) on Monday, November 7th.

Rodman & Renshaw, LLC is a privately-held, full-service investment bank committed to fostering the long-term success of emerging growth companies through capital raising, strategic advice, insightful research, and the development of institutional support.

A live webcast of Aastrom's presentation can be accessed by logging onto the web at http://wsw.com/webcast/rrshq7/astm/. An archived replay of the presentation will also be available after the conference for 90 days, at the same site. For more information about the Rodman & Renshaw Techvest 7th Annual Healthcare Conference, please visit Rodman & Renshaw's website at www.rodmanandrenshaw.com.

About Aastrom Biosciences, Inc.

Aastrom Biosciences, Inc. (Nasdaq: ASTM) is developing patient-specific products for the repair or regeneration of human tissues, utilizing the Company's proprietary adult stem cell technology. Aastrom's strategic position in the tissue regeneration sector is enabled by its proprietary Tissue Repair Cells (TRCs), a mix of bone marrow-derived adult stem and progenitor cells manufactured in the AastromReplicell® System, an industry-unique automated cell production system. TRCs are the core component of the products Aastrom is developing for severe bone fractures, ischemic vascular disease, jaw reconstruction and spine fusion, with Phase I/II level clinical trials active in the U.S. and EU for some of these indications.

For more information, visit Aastrom's website at www.aastrom.com.

This document contains forward-looking statements, including without limitation, statements concerning planned clinical trials, product development objectives, potential advantages of TRCs, and potential product applications, which involve certain risks and uncertainties. The forward-looking statements are also identified through use of the words "planned," and other words of similar meaning. Actual results may differ significantly from the expectations contained in the forward-looking statements. Among the factors that may result in differences are potential patient accrual difficulties, clinical trial results, potential product development difficulties, the effects of competitive therapies, regulatory approval requirements, the availability of financial and other resources and the allocation of resources among different potential uses. These and other significant factors are discussed in greater detail in Aastrom's Annual Report on Form 10-K and other filings with the Securities and Exchange Commission.

CONTACTS:
Kris M. Maly or Becky Anderson
Investor Relations Department
Aastrom Biosciences, Inc.
Phone: (734) 930-5777

Cameron Associates
Kevin McGrath - Institutions
Phone: (212) 245-4577
Alyson Nikulicz - Media
Phone: (212) 554-5464

Day High:
Day Low:
Volume:
on
Copyright West LLC. Minimum 15 minutes delayed.